Astrazeneca Pharma India Faces Short-Term Decline Amidst Strong Long-Term Performance Trends

Astrazeneca Pharma India has experienced a notable decline of 3.2% on April 25, 2025, amidst a broader market downturn. The stock has underperformed its sector, which has seen a decrease of 2.82%. Over the past two days, Astrazeneca has faced consecutive losses, totaling a drop of 4.06%. The stock reached an intraday low of Rs 8,661, reflecting a 2.97% decrease at its lowest point today.
Despite the recent downturn, Astrazeneca Pharma India has shown strong performance metrics over longer periods. In the past month, the stock has gained 2.52%, and over the last three months, it has surged by an impressive 24.36%. Year-to-date, the stock has risen by 17.80%, and over the past year, it boasts a remarkable increase of 61.99%.

In comparison to the Sensex, which has fallen sharply by 1.19% today, Astrazeneca's longer-term performance remains robust, with a three-year increase of 212% and a staggering 880.59% rise over the last decade. The stock continues to maintain higher values than its 20, 50, 100, and 200-day moving averages, indicating a solid market position despite today's challenges.